Nanobiose

Nanobiose commercialises services and products embedding a unique expertise at the crossroad of immunology, toxicology and nanoparticles. Nanobiose is aimed at customers in the pharmaceutical, biotechnological and cosmetics fields of industries who suffer from a lack of efficient and predictive tools to evaluate the immunological safety of their nano-enabled products.

Immunotoxicty risks are badly evaluated along with the R&D process, leading to delays, extra costs, poor allocation of ressources, delayed time to market and ROI, etc. Finally, 10 to 20% of drugs are withdrawn from the market due to immunotoxicity issues ( ex. Althesin (1984, Glaxo), Omniflox (1992, Abbot), Raptiva (2009, Merck)).

Nanobiose offers solutions for more preventive safety evaluation of nano-enabled products like nanomedicines, constrat agents and cosmetics.

Today, Nanobiose promotes the use of human primary cells cultured in a more physiological environment in 3D in order to be as close to reality as possible to the human immune system, as compared to classic 2D culture systems

As of 2019, Nanobiose will bring to the market a fully automated lab-on-a-chip solution to perform a better, faster and cheaper evaluation of nanoparticles safety.